Entrectinib/larotrectinib/selitrectinibAcquired drug resistance: 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1780卷 / 1期

关键词：

D O I：

10.1007/s40278-019-71640-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：149 / 149

相关论文

共 50 条

[1] Larotrectinib/selitrectinibAcquired drug resistance: case report
Reactions Weekly, 2021, 1844 (1) : 251 - 251
[2] Crizotinib/larotrectinib/selitrectinibAcquired resistance following off-label use: case report
Reactions Weekly, 2021, 1852 (1) : 145 - 145
[3] Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion
Delaye, Matthieu
Rodrigues, Manuel
BULLETIN DU CANCER, 2020, 107 (11) : 1085 - +
[4] OsimertinibAcquired drug resistance: 3 case reports
Reactions Weekly, 2021, 1877 (1) : 318 - 318
[5] MogamulizumabRash and drug resistance: 3 case reports
Reactions Weekly, 2024, 2032 (1) : 265 - 265
[6] AntibacterialsAcquired drug resistance: 3 case reports
Reactions Weekly, 2020, 1808 (1) : 42 - 42
[7] CrizotinibAcquired drug resistance: 3 case reports
Reactions Weekly, 2021, 1855 (1) : 128 - 128
[8] LevodopaDyskinesia and drug resistance: 3 case reports
Reactions Weekly, 2021, 1839 (1) : 171 - 171
[9] OsimertinibAcquired drug resistance: 3 case reports
Reactions Weekly, 2023, 1944 (1) : 460 - 460
[10] AntiviralsDevelopment of drug resistance: 3 case reports
Reactions Weekly, 2020, 1809 (1) : 46 - 46

← 1 2 3 4 5 →